KR790001358B1 - Process for the preparation of substituted phenoxy - -methyl propionic acid derivatives - Google Patents

Process for the preparation of substituted phenoxy - -methyl propionic acid derivatives Download PDF

Info

Publication number
KR790001358B1
KR790001358B1 KR7402224A KR740002224A KR790001358B1 KR 790001358 B1 KR790001358 B1 KR 790001358B1 KR 7402224 A KR7402224 A KR 7402224A KR 740002224 A KR740002224 A KR 740002224A KR 790001358 B1 KR790001358 B1 KR 790001358B1
Authority
KR
South Korea
Prior art keywords
phenoxy
reaction
group
substituted phenoxy
propionic acid
Prior art date
Application number
KR7402224A
Other languages
Korean (ko)
Inventor
히데오 후까미
후미히꼬 미요시
요시다까 사꼬
구니오 오오니시
요시끼 나까세
Original Assignee
히라다 다께히꼬
후나이 야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 히라다 다께히꼬, 후나이 야꾸힝고오교 가부시끼가이샤 filed Critical 히라다 다께히꼬
Priority to KR7402224A priority Critical patent/KR790001358B1/en
Application granted granted Critical
Publication of KR790001358B1 publication Critical patent/KR790001358B1/en

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Title compds. [I; Y = CH2-, CH2O-, -CH2CH2-, -CH=CH, R = lower alkyl group or -(CH2)n N-(R1)2 group(n = integer, R' = lower alkyl group) useful as cholesterol-lowering agents, were prepd. by reaction of α-(halogeno-α-methylpropionic acid and P-substituted metal salt of phenol to give α-(P-substituted phenoxy)-α-methyl propionic acid or reactive derivs. (II; X = hydroxyl group or reactive group) followed by reaction with lower alcohols or dimethylamino alcohol.

Description

치환페녹시-α-메틸프로피온산유도체의 제조방법Method for preparing substituted phenoxy-α-methylpropionic acid derivative

본 발명은 콜레스테롤저하작용을 갖는 신규의 치환페녹시-α-메틸프로피온산유도체, 더 상세히 말하면 일반식The present invention is a novel substituted phenoxy-α-methylpropionic acid derivative having cholesterol lowering action, more specifically general formula

Figure kpo00001
Figure kpo00001

[위 일반식에서 Y는 -CH2-, CH2O-, -CH2CH2-, -CH=CH-를 표시하며, R는 저급알킬기 또는

Figure kpo00002
(n은 정수, R1은 저급알킬기)를 표시함.]으로 표시되는 치환페녹시-α-메틸프로피온산유도체(I)의 제조방법에 관한 것이다.[In the above formula, Y represents -CH 2- , CH 2 O-, -CH 2 CH 2- , -CH = CH-, R is a lower alkyl group or
Figure kpo00002
(n represents an integer and R 1 represents a lower alkyl group). The present invention relates to a method for producing a substituted phenoxy-α-methylpropionic acid derivative (I).

사람의 동맥경화증 특히 죽상경하증에 있어서, 혈액중의 콜레스테롤이 중요한 영향을 갖음은 잘 알려진 사실이다. 그러므로 발명자등은 콜레스테롤저하작용을 하는 화합물에 관하여 다각도로 연구하였던바, 상술한 일반식(I)의 화합물이 쥐의 혈청중의 콜레스테롤 농도를 감소시키는 것 및 쥐에 대한 급성독성이 대단히 적다는 것을 알게 되었다.In human arteriosclerosis, especially atherosclerosis, it is well known that cholesterol in blood has a significant effect. Therefore, the inventors have studied in various ways about the compound that lowers cholesterol, and the compound of the general formula (I) mentioned above is very low in reducing the concentration of cholesterol in rat serum and acute toxicity in rats. I learned.

따라서 본 발명의 목적은 사람 및 동물의 동맥경화증 특히 고콜레스테롤혈증(高콜레스테롤血症)질환의 치료 및 예방에 대단히 유용한 신규화합물(I)을 제공하려 하는 것이다.It is therefore an object of the present invention to provide a novel compound (I) which is very useful for the treatment and prevention of atherosclerosis, particularly hypercholesterolemia, in humans and animals.

본 발명의 방법은 다음의 반응식으로 표시한다.The method of the present invention is represented by the following scheme.

Figure kpo00003
Figure kpo00003

(위의 반응식에서 X는 히드록실기 또는 반응성기를 표시하며, Y 및 R는 앞에서 말한 것과 같다.)(In the above scheme, X represents a hydroxyl group or a reactive group, and Y and R are the same as mentioned above.)

즉 본 발명의 방법은 α-(P-치환페녹시)-α-메틸 프로피온산 또는 그 반응성유도체(Ⅱ)를 알코올류(Ⅲ)와 반응시켜서 치환페녹시-α-메틸프로피온산유도체(I)를 제조하는 방법이다.In other words, the method of the present invention produces a substituted phenoxy-α-methylpropionic acid derivative (I) by reacting α- (P-substituted phenoxy) -α-methyl propionic acid or its reactive derivative (II) with alcohols (III). That's how.

아래에서 본 발명을 더 상세히 설명한다.The present invention is explained in more detail below.

본 발명이 사용하는 원료화합물(Ⅱ)은 신규의 화합물인바, 예를들면 P-치환페놀의 금속염에 α-할로게노-α-메틸 프로피온산을 반응시킴으로서 쉽게 제조된다. 또 일반식(Ⅱ)중의 X가 반응성기로 표시되는 화합물로서는 브롬, 클로르 등의 활로겐화물, 산 무수물, 혼합산무수물, 에스테르 등을 들 수 있다.The raw material compound (II) used in the present invention is a novel compound, for example, is easily prepared by reacting α-halogeno-α-methyl propionic acid with a metal salt of P-substituted phenol. Moreover, as a compound in which X in general formula (II) is represented by a reactive group, the borolides, such as bromine and chlor, an acid anhydride, mixed acid anhydride, ester, etc. are mentioned.

그리고 출발원료의 하나인 알코올류(Ⅲ)로서는 예를 들면 메탄올, 에탄올, n-프로판올, 이소프로판올 등의 저급알코올, 디메틸아미노에틸알코올, 디에틸아미노에틸알코올, 디메틸아미노에틸알코올 등의 N·N-디 저급알킬아미노 저급알코올을 예시하는 바이다.As alcohols (III) which are one of the starting materials, for example, lower alcohols such as methanol, ethanol, n-propanol and isopropanol, N.N- such as dimethylaminoethyl alcohol, diethylaminoethyl alcohol and dimethylaminoethyl alcohol Di lower alkylamino lower alcohol is exemplified.

본 발명의 방법을 실시함에 있어서는 출발원료의 하나인 화합물(Ⅱ)로 산 할로겐화물을 사용하는 경우에는 그 반응을 일반적으로 유기용매중에서 수행함이 바람직하다. 유기용매로서는 피리딘, 퀴놀린 등의 염기성용매, 벤젤, 톨루엔, 크실렌 등의 중성용매 등을 들 수 있다. 반응은 빙냉하 또는 실온에서 진행하는바, 경우에 따라서는 40-140℃로 가열하여 반응시간을 단축시킬 수도 있다. 또 중성용매를 사용하는 경우는 제3급아민, 헤테로고리화합물의 존재하에서 반응시킴이 좋은 결과로 되는 경우가 있다.In carrying out the process of the present invention, when an acid halide is used as the compound (II) as one of the starting materials, the reaction is generally carried out in an organic solvent. As an organic solvent, basic solvents, such as pyridine and quinoline, neutral solvents, such as bezel, toluene, and xylene, etc. are mentioned. The reaction proceeds under ice-cooling or at room temperature, and in some cases, the reaction time may be shortened by heating to 40-140 ° C. In the case of using a neutral solvent, it may be a good result to react in the presence of a tertiary amine and a heterocyclic compound.

또 출발원료인 화합물(Ⅱ)로서, X가 히드록실기로 표시되는 카르복실산을 사용하는 경우는 통상의 탈수에스테르화법에 따라서 실시한다, 즉 타측의 출발원료(Ⅲ)인 화합물(Ⅲ)이 메탄올, 에탄올 등의 저급알코올인 경우은, 원료화합물(II)과 원료화합물(Ⅲ)을 환류하에서 반응시키거나 또는 P-톨루엔술폰산등의 에스테르화촉매 존재하에서 환류 반응시킨다, 또 원료화합물(Ⅲ)이 N·N-디저급알칼아미노 저급알코올인 경우는, 벤젠, 톨루엔, 크실렌 등의 유기용매중에서 수분 분리기를 사용하여 환류하에 부생성하는 물을 반응계 밖으로 제거하면서 반응을 수행한다.In addition, when using the carboxylic acid represented by the hydroxyl group as X as a starting material (II), it carries out according to the normal dehydration esterification method, ie, the compound (III) which is the starting material (III) of the other side, In the case of lower alcohols such as methanol and ethanol, the raw material compound (II) and the raw material compound (III) are reacted under reflux or reflux reaction in the presence of an esterification catalyst such as P-toluenesulfonic acid. In the case of N-N-di lower alkali amino lower alcohol, the reaction is carried out while removing by-product water under reflux out of the reaction system using a water separator in an organic solvent such as benzene, toluene, and xylene.

또 원료화합물(Ⅱ)로서 산 무수물을 사용하는 경우는, 반응이 용매 없이도 진행하나, 일반적으로는 유기용매를 사용함이 바람직하며, 이에 합당한 유기용매로는 피리딘, 퀴놀린 등의 함질소헤테로고리화합물, 제3급아민 등의 염기성용매, 벤젠, 톨루엔, 에테르, 디옥산, 크실렌등의 중성용매를 들 수 있다. 그리고 중성용매를 사용시 제3급 아민류, 함질소헤테로고리화합물과의 혼합용매를 사용함이 바람직한 경우가 있다. 또 황산, 플루오루화붕소 등의 촉매를 사용할 수도 있다.In the case of using an acid anhydride as the raw material compound (II), the reaction proceeds without a solvent, but in general, it is preferable to use an organic solvent. Suitable organic solvents include nitrogen-containing heterocyclic compounds such as pyridine and quinoline, Basic solvents, such as tertiary amine, neutral solvents, such as benzene, toluene, ether, dioxane, and xylene, are mentioned. When using a neutral solvent, it is sometimes desirable to use a mixed solvent of tertiary amines and nitrogen-containing heterocyclic compounds. Moreover, catalysts, such as a sulfuric acid and boron fluoride, can also be used.

상술함과 같이하여 얻은 화합물(I)중, R가 N·N-디저급알킬아미노 저급알킬기로 표시되는 화합물은, 통상적인 방법에 의하여 해당하는 유기산 또는 무기산의 염으로 형성시킬 수도 있다.In the compound (I) obtained as mentioned above, the compound in which R is represented by the N * N-di lower alkylamino lower alkyl group can also be formed with the salt of the corresponding organic acid or inorganic acid by a conventional method.

상술함과 같이하여 얻는 화합물(I)의 약리효과는 다음과 같다.The pharmacological effect of the compound (I) obtained by making it above is as follows.

(1) 혈청중의 콜레스테롤에 대한 효과(1) Effect on Cholesterol in Serum

정상적인 SD계의 쥐(체중 160g 전후의 수놈)를 사용하여 10마리를 1군으로 하고 대조용으로 10마리로 되는 1군을 준비한다.A normal SD rat (male of about 160 g body weight) is used as a group of 10 rats and a group of 10 rats is prepared for control.

검체를 투여하기 전에 16시간을 절식시키고, 각종의 검체 및 대조액을 위장내에 경구투여한다. 8시간후에 단무채혈하여 원심처리후 혈청을 분별한다. 혈청중의 콜레스테롤을 Zurkowski-Shibata변법에 의하여 측정한다. 그 결과는 제 1 표와 같다.16 hours are fasted before administering a sample, and various samples and control solutions are orally administered in the stomach. After 8 hours, pickled radish was collected and centrifuged to separate serum. Cholesterol in serum is measured by Zurkowski-Shibata method. The results are shown in the first table.

단, 검체화합물의 투여량은 100mg/kg 쥐체중이며, 각개의 값은 정상적인 쥐의 혈청콜레스테롤값에 대한 피검약물에 의한 억제도를 백분율로 표시하였다.However, the dose of the sample compound was 100 mg / kg rat body weight, and each value expressed the percentage of inhibition by the test drug against the serum cholesterol value of normal rats.

[제 1 표][Table 1]

Figure kpo00004
Figure kpo00004

(2) 쥐에 대한 급성독성(2) Acute Toxicity in Rats

체중 20g 전후의 dd개 쥐(수놈)를 사용하여, 약물을 경구로 투여하고 Lichfilcl-Wilconzon법[J. Pharmac. Exp. Ther, 96, 99(1949)]근거하여 각기 LD50의 값을 구한다. 그 결과는 제 2 표와 같다. 단 Y 및 R는 (1)과 같다.Drugs were orally administered using dd rats (males) at around 20 g of body weight and subjected to the Lichfilcl-Wilconzon method [J. Pharmac. Exp. Ther, 96, 99 (1949)], respectively, to find the value of LD 50 . The results are shown in the second table. Provided that Y and R are the same as (1).

[제 2 표][Table 2]

Figure kpo00005
Figure kpo00005

(3) 공지의 화합물과 본 발명 화합물과의 약리활성 및 독성비교(3) Pharmacological activity and toxicity comparison between known compounds and compounds of the present invention

(I)혈청중의 콜레스테롤에 대한 효과 :(I) the effect on cholesterol in serum:

10마리를 1군으로 형성시킨 Wistar계의 쥐(수놈)(체중 약 250g) 12군을 사용하여, 그 11군의 각군에 대하여는 약물 360mg/kg(각개의 시험약물은 5% 아라비아 검의 용액에 현탁시킨 형태로 하여 사용하였다)의 비율로 강제적을 경구투여 하였다. 그리고 대조군에는 5% 아라비아 검을 상술함과 같이 투여한다. 투여를 끝낸 다음 24시간 경과후에 마취시켜서 총경동맥으로 부터 채혈하여, 원심처리후에 혈청을 분리한다. 혈청중의 콜레스테롤 총량을 Rudel-Morris법(J.Lipid Res. 14,354(1973)에 의하여 정량하고, 대조군에 대한 피검약물의 억제도를 백분율로 표시하였다.Wistar rats (males) (about 250g body weight) were formed in groups of 10, and 12 groups were used. For each group of the 11 groups, the drug was 360 mg / kg (each test drug in 5% Arabic gum solution). Forced administration was carried out at the ratio of (suspended form). And 5% Arabian gum is administered to the control as described above. 24 hours after the end of the administration, anesthesia was collected and collected from the total carotid artery, and serum was separated after centrifugation. The total amount of cholesterol in serum was quantified by the Rudel-Morris method (J.Lipid Res. 14,354 (1973)), and the inhibitory degree of the test drug to the control group was expressed as a percentage.

그 결과는 제 3 표에 표시한 바와 같다.The results are as shown in the third table.

[제 3 표][Table 3]

Figure kpo00006
Figure kpo00006

(II) 마우스에 대한 급성독성 :(II) Acute Toxicity in Mice:

체중 20g 전후이고 건전한 dd게 쥐(수놈)를 사용하여, 약물을 경구투여하고 Lichfild Wilcoxon 법에 의하여 각기 LD50의 값을 구한다. 그 결과는 제 4 표와 같다. 단 표에 기재한 약물 A-I는 제 3 표 중의 그것들과 동일하다.Using healthy rats (males) at around 20 g body weight, the drug is orally administered and the values of LD 50 are determined by the Lichfild Wilcoxon method. The results are shown in the fourth table. Drug AI described in the table is the same as those in the third table.

[제 4 표][Table 4]

Figure kpo00007
Figure kpo00007

다음에서는 실시예를 들고서 설명한다.Next, it demonstrates with an Example.

[실시예 1]Example 1

α-[P-(P'- 클로르벤질)페녹시]-α-메틸프로피온산 3.1g을 무수에탄올 40ml에 용해하고, P-톨루엔술폰산 0.2g을 첨가하고서 3시간 가열 환류한다. 반응이 끝난 다음에 과잉분의 용매를 증류제거하고, 잔사를 에테르에 용해하여 수세 건조후 용매를 증류 제거하고 잔사인 액체를 감압증류하여, 비등점이 185-186℃/2mmHg인 α-[P-(P'-클로르벤질)페녹시]-α-메틸프로피온산 에틸에스테르인 투명액체를 얻는다.3.1 g of α- [P- (P'-chlorbenzyl) phenoxy] -α-methylpropionic acid is dissolved in 40 ml of ethanol anhydride, and 0.2 g of P-toluenesulfonic acid is added and heated to reflux for 3 hours. After completion of the reaction, the excess solvent was distilled off, the residue was dissolved in ether, washed with water, the solvent was distilled off, the residue was distilled off under reduced pressure, and the boiling point was 18-186 ° C./2 mmHg. Obtain a transparent liquid which is (P'-chlorbenzyl) phenoxy]-(alpha)-methyl propionic acid ethyl ester.

원소분석치 : C19H21O3ClElemental Analysis Value: C 19 H 21 O 3 Cl

이론치(%) : C 68.57, H 6.36Theoretic value (%): C 68.57, H 6.36

분석치(%) : C 68.38, H 6.53Analytical Value (%): C 68.38, H 6.53

[실시예 2]Example 2

α-[P-(P'-클로르벤질옥시)페녹시]-α-메틸프로피온산 4.0g을 무수메탄올 40ml에 용해하고, P-톨루엔술폰산 0.2g을 첨가하고서 4시간 가열 환류한다.4.0 g of α- [P- (P'-chlorbenzyloxy) phenoxy] -α-methylpropionic acid is dissolved in 40 ml of anhydrous methanol, and 0.2 g of P-toluenesulfonic acid is added and heated to reflux for 4 hours.

반응이 완결후에, 과잉의 메탄올을 증류 제거하고, 잔사를 실시예 1과 같이 처리하여 얻는 결정을 메탄올로 재결정하여 융점이 86-87℃로 표시되는 α-[P-(P'- 클로르벤질옥시)페녹시]-α-메틸프로피온산 메틸에스테르의 백색 결정을 얻는다.After the completion of the reaction, excess methanol was distilled off, and the crystal obtained by treating the residue as in Example 1 was recrystallized with methanol to give?-[P- (P'-chlorbenzyloxy) having a melting point of 86-87 占 폚. ) Phenoxy] -α-methylpropionic acid methyl ester is obtained.

원소분석치 : C18H10O4ClElemental Analysis Value: C 18 H 10 O 4 Cl

이론치(%) : C 64.58, H 5.72Theoretic value (%): C 64.58, H 5.72

분석치(%) : C 64.47, H 5.57Analytical Value (%): C 64.47, H 5.57

[실시예 3]Example 3

크실렌 40ml에 α-[P-(P'-클로르스티릴)페녹시]-α-메틸프로피온산 3.2g과 N,N-디에틸아미노에탄올 1.2g을 첨가하고 수분 분리기를 착설한 다음 6시간동안 환류 교반한다. 반응혼합물을 물에 주가하고서 에테르로 추출한다. 에테르추출액을 묽은 탄산나트륨 수용액으로 또 다음에는 물로 세척한 후에 건조한다. 다음에는 건조한 염화수소 기체를 도입하여 석출하는 결정을 여과하여 분별수득하고 에탄올로 재결정하여 융점 174-176.5℃인 α-[P-(P'- 클로르스티릴)페녹시]-α-메틸프로피온산 N, N-디에틸아미노에틸에스테르 염산염을 백색결정으로 얻는다.To 40 ml of xylene, 3.2 g of α- [P- (P'-chlorstyryl) phenoxy] -α-methylpropionic acid and 1.2 g of N, N-diethylaminoethanol were added, and a water separator was installed. The mixture was refluxed for 6 hours. Stir. The reaction mixture is added to water and extracted with ether. The ether extract is washed with dilute aqueous sodium carbonate solution and then washed with water and dried. Next, the precipitated crystals were introduced by the introduction of dry hydrogen chloride gas, and the precipitates were collected by filtration and recrystallized with ethanol to give α- [P- (P'-chlorstyryl) phenoxy] -α-methylpropionic acid N, N-diethylaminoethyl ester hydrochloride is obtained as white crystals.

원소분석치 : C24H31O3NCl2 Elemental Analysis Value: C 24 H 31 O 3 NCl 2

이론치(%) : C 63.86, H 6.70, H 3.10Theoretic value (%): C 63.86, H 6.70, H 3.10

분석치(%) : C 63.90, H 7.00, N 2.92Analytical Value (%): C 63.90, H 7.00, N 2.92

[실시예 4]Example 4

크실렌 50ml에 α-[P-(P'-클로르벤질옥시)페녹시]-α-메틸프로피온산 1.6g과 N, N-디메틸아미노에탄올 0.5g을 첨가하고 수분 분리기를 착설한 환류 교반하면서 6시간동안 반응시킨다. 반응 완료 후는 실시예 3의 그것과 같이 처리하여 얻는 결정을 이소프로필 일코올로 재결정하여 녹는점 101-103℃ α-[P-(P'-클로르벤질옥시)페녹시]-α-메틸프로피온산 N,N-디메틸아미노에틸에스테르 염산염을 백색결정으로 얻는다.To 50 ml of xylene, 1.6 g of α- [P- (P'-chlorbenzyloxy) phenoxy] -α-methylpropionic acid and 0.5 g of N and N-dimethylaminoethanol were added, and a water separator was installed under reflux stirring for 6 hours. React. After completion of the reaction, the crystals obtained by treatment in the same manner as in Example 3 were recrystallized from isopropyl alcohol to have a melting point of 101-103 ° C. α- [P- (P'-chlorbenzyloxy) phenoxy] -α-methylpropionic acid N, N-dimethylaminoethyl ester hydrochloride is obtained as white crystals.

원소분석치 : C21H27O4Cl2NElemental Analysis Value: C 21 H 27 O 4 Cl 2 N

이론치(%) : C 58.88, H 6.35, H 3.27Theoretic value (%): C 58.88, H 6.35, H 3.27

실험치(%) : C 58.10, H 6.41, N 2.97Experimental value (%): C 58.10, H 6.41, N 2.97

[실시예 5]Example 5

벤젠 40ml에 α-[P-(P'-클로르스티릴)페녹시]-α-메틸프로피온산 6.0g을 용해하고 실온서 교반하면서 벤젠 20ml에 N,N-디메틸아미노에탄올 1.0g을 용해한 용액을 15분간에 긍하여 적가한다. 다음에는 1.5시간동안 환류 교반하면서 반응시킨다. 반응 완료 후에 실온으로 냉각하여 생성하는 결정여과분취하여 건조하고 이소프로필알코올로 재결정하여 융점 188-191℃ α-[P-(P'-클로르스티릴)페녹시]-α-메틸프로피온산 N, N-디메틸아미노에틸에스테르 염산염을 백색결정으로 얻는다.6.0 g of α- [P- (P'-chlorstyryl) phenoxy] -α-methylpropionic acid was dissolved in 40 ml of benzene, and 1.0 g of N, N-dimethylaminoethanol was dissolved in 20 ml of benzene while stirring at room temperature. Emphatically in minutes. Next, the reaction was stirred under reflux for 1.5 hours. After completion of the reaction, the resulting crystal filtration was cooled to room temperature, dried and recrystallized from isopropyl alcohol to give a melting point of 188-191 ° C α- [P- (P'-chlorstyryl) phenoxy] -α-methylpropionic acid N, N -Dimethylaminoethyl ester hydrochloride is obtained as white crystals.

원소분석치 : C22H27O3Cl2NElemental Analysis Value: C 22 H 27 O 3 Cl 2 N

이론치(%) : C 62.27, H 6.41, H 3.30Theoretic value (%): C 62.27, H 6.41, H 3.30

실험치(%) : C 62.04, H 6.40, N 3.12Experimental value (%): C 62.04, H 6.40, N 3.12

[실시예 6]Example 6

아세토니트릴 80ml에 α-[P-(P'- 클로르벤질옥시)페녹시]-α-메틸프로피온산 5.0g과 N, N-디시클로헥실카르보디이미드 2.0g을 첨가하고 실온에서 교반하여 2시간 반응시킨 다음 1야동안 방치한다. 석출하는 N, N-디시클로헥실요소를 여과 분별하고 여액을 감압증류하여 용매를 제거한다. 증류잔사를 에에테르 : 리그로인 혼합용매로 재결정하여 녹는점 116-117℃인 α-[P-(P'-클로르벤질옥시)페녹시]-α-메틸프로피온산 무수물을 백색결정으로 얻는다.To 80 ml of acetonitrile, 5.0 g of α- [P- (P'-chlorbenzyloxy) phenoxy] -α-methylpropionic acid and 2.0 g of N and N-dicyclohexylcarbodiimide were added and stirred at room temperature for 2 hours. And leave for 1 night. The precipitated N, N-dicyclohexyl urea is filtered off and the filtrate is distilled under reduced pressure to remove the solvent. The distillation residue is recrystallized with an ether: ligroin mixed solvent to obtain α- [P- (P'-chlorbenzyloxy) phenoxy] -α-methylpropionic anhydride having a melting point of 116-117 ° C. as a white crystal.

원소분석치 : C34H32O7Cl2 Elemental Analysis Value: C 34 H 32 O 7 Cl 2

이론치(%) : C 65.49, H 5.17Theoretic value (%): C 65.49, H 5.17

실험치(%) : C 65.66, H 5.23Experimental value (%): C 65.66, H 5.23

[실시예 7]Example 7

피리딘 4ml에 α-[P-(P'-클로르벤질옥시)페녹시]-α-메틸프로피온산 무수물 1.0g과 n-프로판을 1.2g을 용해하고 80-95℃에서 4시간 가열한 다음 1 야간 방치한다. 반응액을 감압 농축하여 잔사를 에테르에 용해하고 묽은 탄산수소나트륨 수용액으로 다음에는 물로 세척한 후에 건조한다. 에테르를 증류 제거하고 잔사를 이소프로필 알코올로 재결정하여 융점 42-43.5℃인 α-[P-(P'- 클로르벤질옥시)페녹시]-α-메틸프로피온산 n-프로필에스테르를 백색결정으로 얻는다.1.0 g of α- [P- (P'-chlorbenzyloxy) phenoxy] -α-methylpropionic anhydride and 1.2 g of n-propane were dissolved in 4 ml of pyridine, and heated at 80-95 ° C. for 4 hours, and then left to stand overnight. do. The reaction solution is concentrated under reduced pressure, and the residue is dissolved in ether, and then washed with water with dilute sodium bicarbonate solution and then dried with water. The ether was distilled off and the residue was recrystallized from isopropyl alcohol to obtain α- [P- (P'-chlorbenzyloxy) phenoxy] -α-methylpropionic acid n-propyl ester having a melting point of 42-43.5 ° C as white crystals.

원소분석치 : C20H23O4ClElemental Analysis Value: C 20 H 23 O 4 Cl

이론치(%) : C 66.20, H 6.39Theoretic value (%): C 66.20, H 6.39

실험치(%) : C 65.37, H 6.43Experimental value (%): C 65.37, H 6.43

Claims (1)

일반식General formula
Figure kpo00008
Figure kpo00008
(위 일반식에서 Y는 -CH2-, CH2O-, -CH2CH2-, CH=CH-를 등의 기를, X는 히드록실기 또는 반응성기를 표시한다.)로 표시되는 α-(P-치환페녹시)-α-메틸프로피온산 또는 그 반응성유도체를 일반식 ROH(이 일반식에서 R는 저급 알칼기 또는
Figure kpo00009
기 이다. 단 n은 정수, R1은 저급알킬기를 표시한다.)로 표시되는 알코올류와 반응시킴을 특징으로 하는 일반식
(In the above general formula, Y represents -CH 2- , CH 2 O-, -CH 2 CH 2- , CH = CH-, etc., X represents a hydroxyl group or a reactive group.) P-substituted phenoxy) -α-methylpropionic acid or its reactive derivative is represented by the formula ROH (wherein R is a lower
Figure kpo00009
Is. Provided that n is an integer and R 1 represents a lower alkyl group.
Figure kpo00010
Figure kpo00010
(위 일반식에서 Y 및 R는 전술한 바와 같다.)로 표시되는 치환페녹시-α-메틸프로피온산유도체의 제조방법.(Y and R in the general formula is as described above.) A method for producing a substituted phenoxy-α-methylpropionic acid derivative.
KR7402224A 1974-04-17 1974-04-17 Process for the preparation of substituted phenoxy - -methyl propionic acid derivatives KR790001358B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR7402224A KR790001358B1 (en) 1974-04-17 1974-04-17 Process for the preparation of substituted phenoxy - -methyl propionic acid derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR7402224A KR790001358B1 (en) 1974-04-17 1974-04-17 Process for the preparation of substituted phenoxy - -methyl propionic acid derivatives

Publications (1)

Publication Number Publication Date
KR790001358B1 true KR790001358B1 (en) 1979-09-28

Family

ID=19200005

Family Applications (1)

Application Number Title Priority Date Filing Date
KR7402224A KR790001358B1 (en) 1974-04-17 1974-04-17 Process for the preparation of substituted phenoxy - -methyl propionic acid derivatives

Country Status (1)

Country Link
KR (1) KR790001358B1 (en)

Similar Documents

Publication Publication Date Title
US4251520A (en) Glucofuranose derivatives
US2895992A (en) Process for the production of benzoic
DE2541342A1 (en) NEW PHENOXYALKYLCARBONIC ACIDS AND METHOD FOR PREPARING THE SAME
NL8004081A (en) METHOD FOR PREPARING A PHARMACEUTICAL PREPARATION WITH ANALGETIC AND ANTI-INFLAMMATORY ACTION, USING FORMED PREPARATION THEREOF AND METHOD FOR PREPARING AN ESTER OF 4- (2-CARBOXYLIFLOROXYL-FLOROXYL-FLOROXYL-FLOROXYL-FLOROXYL-FLOROXYL-FLOROXYL-FLOROXYL-FLOROXYL] 8-TRIFLUORMETHYLCHINOLINE.
EP0094102A2 (en) 1-(1-Cyclohexanyl-methyl) pyrrolidine derivatives, and process for their preparation
US3105854A (en) Meta-substituted phenoxyethylamines
KR790001358B1 (en) Process for the preparation of substituted phenoxy - -methyl propionic acid derivatives
JPS6312063B2 (en)
EP0214004B1 (en) 4-oh-quinoline-carboxylic-acid derivatives substituted in position 2 by a dihydroxy-substituted group, possibly etherified or esterified, process and intermediates for their preparation, their use as medicaments and compositions containing them
US4233304A (en) Pyridoxine derivatives
US4024280A (en) Abietanilides, their production and use
EP0002401B1 (en) Derivatives of naphthalene, process for their preparation and their therapeutic application
US2528940A (en) Pyrrolidylethyl indole compounds
US2625566A (en) Beta-(ortho-methoxy) phenyl-isopropyl benzyl alkyl amines and salts thereof
EP0445039B1 (en) Pyridylsulfonylurea and pyridylsulfonylthiourea derivatives, process for their preparation and pharmaceutical compositions containing them
US4260613A (en) Pyridoxine derivatives
JPS61267542A (en) Aminobenzamide compound
EP0254611B1 (en) Derivatives of 8-phenylthiotetrahydroquinolines and their salts, their synthesis for use as medicaments and compositions containing them
WO1991005772A1 (en) Novel dihydro-1,2 oxo-2 quinoxaline derivates, their preparation and their application in therapeutics
KR800001450B1 (en) Process for the preparation of 1,3,5-trisubstitude benzene derivative
CA1064489A (en) Process for the preparation of new benzenesulfonamides
US4017623A (en) Esters of 2-[(4-quinolyl)amino]-benzoic acids in analgesic and anti-inflammatory compositions
KR840000766B1 (en) Process for preparing bismoranolin derivatives
EP0210885B1 (en) Derivatives of primary halobiphenyl alcohols therapeutically useful in the treatment of arteriosclerosis
KR800001132B1 (en) Process for preparing 5-sulfamoyl benzoic acid substituted by heferocyclic compound